A Review on the Relationship between SGLT2 Inhibitors and Cancer
Open Access
- 1 January 2014
- journal article
- review article
- Published by Wiley in International Journal of Endocrinology
- Vol. 2014, 1-6
Abstract
Risk of increasing breast and bladder cancer remains a safety issue of SGLT2 (sodium glucose cotransporter type 2) inhibitors, a novel class of antidiabetic agent. We reviewed related papers published before January 29, 2014, through Pubmed search. Dapagliflozin and canagliflozin are the first two approved SGLT2 inhibitors for diabetes therapy. Although preclinical animal toxicology did not suggest a cancer risk of dapagliflozin and overall tumor did not increase, excess numbers of female breast cancer and male bladder cancer were noted in preclinical trials (without statistical significance). This concern of cancer risk hindered its approval by the US FDA in January, 2012. New clinical data suggested that the imbalance of bladder and breast cancer might be due to early diagnosis rather than a real increase of cancer incidence. No increased risk of overall bladder or breast cancer was noted for canagliflozin. Therefore, the imbalance observed with dapagliflozin treatment should not be considered as a class effect of SGLT2 inhibitors and the relationship with cancer for each specific SGLT2 inhibitor should be examined individually. Relationship between SGLT2 inhibition and cancer formation is still inconclusive and studies with larger sample size, longer exposure duration, and different ethnicities are warranted.Keywords
Funding Information
- National Science Council (NSC102-2314-B-002-067)
This publication has 50 references indexed in Scilit:
- SGLT-2 inhibitors and their potential in the treatment of diabetesDiabetes, Metabolic Syndrome and Obesity, 2013
- Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studiesBMC Cancer, 2013
- MAP17 and SGLT1 Protein Expression Levels as Prognostic Markers for Cervical Tumor Patient SurvivalPLOS ONE, 2013
- Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in TaiwanBMC Cancer, 2013
- Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort studyDiabetologia, 2012
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participantsThe Lancet, 2011
- Risk of Bladder Cancer Among Diabetic Patients Treated With PioglitazoneDiabetes Care, 2011
- SGLT-2 Inhibitors in Development for Type 2 Diabetes TreatmentThe Review of Diabetic Studies, 2011
- Urinary tract infections and reduced risk of bladder cancer in Los AngelesBritish Journal of Cancer, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008